A quantified approach to the analysis and prevention of urinary complications in radiotherapeutic treatment of cancer of the cervix

Einfluß der Geometrie von Brachytherapieapplikatoren auf die Dosisverteilung im Becken bei Patientinnen mit Zervixkarzinom

“…Pourquier et al [21,22] discovered a much larger influence of dose delivered by brachytherapy, compared to EBRT, on complication rate in bladder and rectosigmoid. ICRU [10] recommended 60 Gy reference volume seems to be less strongly correlated with complication rate [20,21,30]. Every effort should then be paid to minimise doses to critical organs without worsening other parameters, which could infiuence local control, such as the point A dose.…”

“…Since a good correlation between the dose to critical organs and complication rate and severity was found [4,6,16,17,24], with particular influence of the dose from brachytherapy [21,22], these modifications may be a way to improve therapeutic ratio of cervical cancer radiotherapy. However, all these improvements are secondary to restrictions put by applicator geometry extorted by patients' anatomical conditions.…”

Long term results of definitive radiotherapy for cervical carcinoma using four applications of high dose rate afterloading

“…[33][34][35] In our patients, rectal dosimetry during the afterloading application had no predictive or therapeutic value. However, rectal dosimetry is a simple, safe measure and must not be omitted.…”

Strahlentherapie des Zervixkarzinoms

“…Nonetheless, there are still varying irradiation and treatment strategies and very different patient populations, which makes a direct comparison of the results and the side effects of therapy difficult.The decision in favour of radiotherapy should therefore not be based on published treatment results alone, but also on the options available on the spot. Die Brachytherapiedosis wurde in mgh angegeben und betrug dann zwischen 3290 und 6543 mgh [51].…”

“…Bei den 1383 Patientinnen, die in den 9 französischen Zentren behandelt wurden, traten im Stadium I und IIa in 3% Grad-III-Nebenwirkungen am Darm auf, im Stadium IIb und III waren es dagegen 7%. Die Nebenwirkungen an der Blase bei der gleichen Studie wurde von Pourquier [51] analysiert: Er fand insgesamt bei 2% der Patientinnen Nebenwirkungen an der Blase, wobei Grad III mit einer kumulativen Dosis aus Tele-und Brachytherapie von 84 Gy Referenzdosis, Grad II von 77 Gy und Grad I von 70 Gy korrelierte.…”